Molecular Technologist I-III
Tempus AI
Summary
Passionate about precision medicine and advancing the healthcare industry? Recent advancements in underlying technology have finally made it possible for AI to impact clinical care in a meaningful way. Tempus' proprietary platform connects an entire ecosystem of real-world evidence to deliver real-time, actionable insights to physicians, providing critical information about the right treatments for the right patients, at the right time.
Job description
Shift: Sunday-Wednesday (7:00am-5:30pm)
Responsibilities
- Work with a cutting-edge genomics workflow to provide high-quality next-generation sequencing data with rapid turnaround times in a clinical laboratory.
- Perform routine testing, quality control, calibration, maintenance and proficiency testing in accordance with current laboratory procedures.
- Perform complex molecular-based procedures with a high degree of quality and in accordance with established protocols.
- Perform next-generation sequencing, including nucleic acid extraction, DNA/RNA quantification and qualification, NGS library preparation, probe hybridization, probe/library capture, library cleanup and quantification, loading sequencing libraries onto the Illumina Nextseq, HiSeq4000, and Novaseq.
- Sterilizing laboratory equipment and workspaces as assigned.
- Entering clinical patient data into the Laboratory Information Management system.
- Obtain 12 continuing education hours in the field of oncology or molecular biology.
- Maintain competency to perform all assigned molecular biology protocols in accordance with CAP, CLIA, NYSDOH regulations.
Qualifications
Must have one of the following educational requirements:
- MS in medical technology, clinical laboratory science, chemical, physical or biological science and 1 year pertinent clinical laboratory experience with molecular biology
- BS/BA in medical technology, clinical laboratory science, chemical, physical or biological science and 1 year of pertinent clinical lab experience in molecular biology
- Excellent communication skills
- Thrives in a fast-paced environment
- Ability to work with others to plan and carry out scientific programs
- Self-driven and works well in an interdisciplinary team with minimal direction
- Strong desire to build products that will save lives and change the course of cancer
- Impeccable attention to detail
Highly Desirable
- Experience with next-generation sequencing
- Work in a CLIA/CAP high-complexity laboratory
- Experience with robotics and automated liquid handling systems
- Knowledge of LIMS platforms and various computer systems
Requirements
- MS in medical technology, clinical laboratory science, chemical, physical or biological science and 1 year pertinent clinical laboratory experience with molecular biology, OR BS/BA in medical technology, clinical laboratory science, chemical, physical or biological science and 1 year of pertinent clinical lab experience in molecular biology
- Excellent communication skills
- Thrives in a fast-paced environment
- Ability to work with others to plan and carry out scientific programs
- Self-driven and works well in an interdisciplinary team with minimal direction
- Strong desire to build products that will save lives and change the course of cancer
- Impeccable attention to detail
- Experience with next-generation sequencing (highly desirable)
- Work in a CLIA/CAP high-complexity laboratory (highly desirable)
- Experience with robotics and automated liquid handling systems (highly desirable)
- Knowledge of LIMS platforms and various computer systems (highly desirable)
Company overview
Tempus AI, Inc. (NASDAQ: TEM) is a pioneering healthcare technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company was established after Lefkofsky's wife was diagnosed with breast cancer, driving his mission to revolutionize cancer care through technology and artificial intelligence. Tempus specializes in applying AI to advance precision medicine by collecting and analyzing vast amounts of molecular, clinical, and genomic data. The company operates across multiple therapeutic areas including oncology, cardiology, radiology, neurology, psychiatry, and dermatology. Tempus provides comprehensive diagnostic services including next-generation sequencing (NGS), PCR profiling, and molecular pathology testing. Its AI-powered platform enables physicians to make real-time, data-driven decisions for personalized patient care and targeted therapies. The company went public in June 2024 and has expanded globally with operations in multiple countries. Tempus continues to innovate at the intersection of healthcare and artificial intelligence, aiming to ensure patients receive the right treatments at the right time for improved health outcomes.